Search Result

Results for "

Bacteroides fragilis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (14) Bacterial (16) Biochemical Assay Reagents (2) DNA/RNA Synthesis (11) Endogenous Metabolite (1) Glycosidase (2) Insecticide (1) Isotope-Labeled Compounds (2) LDLR (1) Parasite (8) Reference Standards (4) Topoisomerase (8)
By Research Areas:	Cardiovascular Disease (2) Endocrinology (1) Infection (16) Inflammation/Immunology (9) Metabolic Disease (3)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1907

Rifamycin sodium 2 Publications Verification Rifamycin SV sodium	Antibiotic Bacterial DNA/RNA Synthesis	Infection Inflammation/Immunology
Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-B0147

Pefloxacin 3 Publications Verification Pefloxacinium	Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B1907A

Rifamycin 2 Publications Verification Rifamycin SV	Antibiotic Bacterial DNA/RNA Synthesis	Infection
Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-B0147A

Pefloxacin mesylate 3 Publications Verification Pefloxacinium mesylate	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies .

HY-132177H

exo-α-Fucosidase, Bacteroides fragilis	Biochemical Assay Reagents	Others
exo-α-Fucosidase, Bacteroides fragilis (EC 3.2.1.51) is a glycoside hydrolase that would release free fucose .

HY-P11452

(KKEEE)3K	LDLR	Endocrinology
(KKEEE)3K is a kidney-targeting peptide. (KKEEE)3K enters renal tubular cells via megalin receptor-mediated endocytosis. (KKEEE)3K can be used in the research of renal drug delivery .

HY-B0147B

Pefloxacin mesylate dihydrate 3 Publications Verification Pefloxacinium mesylate dihydrate	Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate dihydrate is a broad spectrum antibiotic. Pefloxacin mesylate dihydrate blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate dihydrate inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate dihydrate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate dihydrate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate dihydrate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate dihydrate can be used for infection studies .

HY-159955

DC-159a	Bacterial	Infection
DC-159a is an 8-methoxyfluoroquinolone with broad-spectrum antimicrobial activity, especially against Gram-positive pathogens. DC-159a against Peptostreptococcus, Clostridium difficile, and Bacteroides fragilis with MIC₉₀ values of 0.5, 4, and 2 μg/mL, respectively .

HY-19428A

Ranbezolid hydrochloride RBx-7644	Antibiotic Bacterial	Infection Cardiovascular Disease
Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC₅₀ of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .

HY-19428

Ranbezolid RBx7644 free base	Antibiotic Bacterial	Infection Cardiovascular Disease
Ranbezolid (RBx7644 free base) is an orally active, oxazolidinone antibiotic against Gram-positive and Gram-negative anaerobes including Staphylococcus aureus, Staphylococcus epidermidis and Bacteroides fragilis. Ranbezolid can inhibit the 50s ribosomal subunit with an IC₅₀ of 17 μM for bacterial ribosomes. Ranbezolid interferes cell wall and lipid synthesis. Ranbezolid can rapidly kill bacteria, significantly reduce bacterial load, and has better cardiovascular safety. Ranbezolid can be used for the study of antibiotics for anaerobic bacteria .

HY-105213

YM-17K MC-352	Antibiotic Bacterial	Infection
YM-17K (MC-352) is a macrolide antibiotic. YM-17K exhibits antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobic bacteria. YM-17K exhibits stable activity in serum and is less affected by pH values .

HY-B2193E

α-Amylase, Bacteroides fragilis	Endogenous Metabolite	Metabolic Disease
α-Amylase, Bacteroides fragilis (EC 3.2.1.1) is a protein enzyme that hydrolyses alpha bonds of large, alpha-linked polysaccharides, such as starch and glycogen, yielding glucose and maltose.

HY-P2858C

β-Mannosidase, Bacteroides fragilis	Glycosidase	Metabolic Disease
β-Mannosidase, Bacteroides fragilis (EC 3.2.1.25), is the final exoglycosidase in the N-linked glycoprotein oligosaccharide catabolism pathway. β-Mannosidase catalyzes the following chemical reaction: hydrolysis of the terminal non-reducing β-D-mannose residue in β-D-mannoside.

HY-E71229

α-Galactosidase 110A, Bacteroides fragilis	Biochemical Assay Reagents	Others
α-Galactosidase 110A, Bacteroides fragilis (EC 3.2.1.-) is a glycoside hydrolase enzyme that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It is encoded by the GLA gene. Two recombinant forms of alpha-galactosidase are called agalsidase alfa (INN) and agalsidase beta (INN) .

HY-P2775D

β-Glucosidase, Bacteroides fragilis	Glycosidase	Metabolic Disease
β-Glucosidase, Bacteroides fragilis (EC 3.2.1.21), is a glucosidase that acts on the β1→4 glycosidic bond connecting two glucose molecules or glucose-substituted molecules (e.g., disaccharide cellobiose). β-Glucosidase is an exonuclease specific for a variety of β-D-glycosidic substrates. β-Glucosidase catalyzes the hydrolysis of the terminal non-reducing residues of β-D-glucosides, releasing glucose.

HY-B1907R

Rifamycin sodium (Standard) Rifamycin SV sodium (Standard)	Reference Standards Bacterial Antibiotic	Infection
Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-B0147S1

Pefloxacin-d3 Pefloxacinium-d₃	Isotope-Labeled Compounds Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147S

Pefloxacin-d5 Pefloxacinium-d₅	Isotope-Labeled Compounds Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin-d₅ (Pefloxacinium-d₅) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147R

Pefloxacin (Standard) Pefloxacinium (Standard)	Reference Standards Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Standard) (Pefloxacinium (Standard)) is the analytical standard of Pefloxacin (HY-B0147). This product is intended for research and analytical applications. Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147AR

Pefloxacin mesylate (Standard) Pefloxacinium mesylate (Standard)	Reference Standards Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin mesylate (Standard) (Pefloxacinium mesylate (Standard)) is the analytical standard of Pefloxacin mesylate (HY-B0147A). This product is intended for research and analytical applications. Pefloxacin (Pefloxacinium) mesylate is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate can be used for infection studies .

HY-B0147BR

Pefloxacin mesylate dihydrate (Standard) Pefloxacinium mesylate dihydrate (Standard)	Reference Standards Topoisomerase DNA/RNA Synthesis Antibiotic Bacterial Parasite	Infection Inflammation/Immunology
Pefloxacin (Pefloxacinium) mesylate dihydrate (Standard) is the analytical standard of Pefloxacin mesylate dihydrate (HY-B0147B). This product is intended for research and analytical applications. Pefloxacin (Pefloxacinium) mesylate dihydrate is a broad spectrum antibiotic. Pefloxacin mesylate dihydrate blocks DNA replication by inhibiting DNA gyrase. Pefloxacin mesylate dihydrate inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin mesylate dihydrate exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin mesylate dihydrate has anti-Plasmodium yoelii infection activity. Pefloxacin mesylate dihydrate increase UVA-induced edema and immunesuppression. Pefloxacin mesylate dihydrate can be used for infection studies .

HY-E71055A

Glycogen branching enzyme, Bacteroides fragilis

HY-119475

Satranidazole	Bacterial Insecticide DNA/RNA Synthesis	Infection
Satranidazole is an orally active insecticide and antimicrobial agent with high electron affinity. Satranidazole forms reduced nitro intermediates, which interact with DNA, causing helix instability, strand breakage and release of thymidine derivatives. Satranidazole exhibits antitrichomonal activity against Trichomonas vaginalis and Trichomonas foetus, and antiamoebic activity in rodent models of hepatic amoebiasis and caecal amoebiasis. Satranidazole inhibits the replication of bacteriophage φX174 DNA. Satranidazole can be used in research related to caecal amoebiasis, trichomoniasis and anaerobic bacterial infections .

Cat. No.	Product Name	Target	Research Area

HY-P11452

(KKEEE)3K	LDLR	Endocrinology
(KKEEE)3K is a kidney-targeting peptide. (KKEEE)3K enters renal tubular cells via megalin receptor-mediated endocytosis. (KKEEE)3K can be used in the research of renal drug delivery .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1907

Rifamycin sodium 2 Publications Verification Rifamycin SV sodium	Infection Microorganisms Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Antibiotic Bacterial DNA/RNA Synthesis
Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-B0147

Pefloxacin 3 Publications Verification Pefloxacinium	Infection Classification of Application Fields Disease Research Fields	Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase
Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B1907R

Rifamycin sodium (Standard) Rifamycin SV sodium (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic
Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

Cat. No.	Product Name	Chemical Structure

HY-B0147S1

Pefloxacin-d3
Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

Pefloxacin-d3

Pefloxacin-d₃ (Pefloxacinium-d₃) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

HY-B0147S

Pefloxacin-d5
Pefloxacin-d₅ (Pefloxacinium-d₅) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

Pefloxacin-d5

Pefloxacin-d₅ (Pefloxacinium-d₅) is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin (Pefloxacinium) is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC₅₀ of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC₉₀s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks